Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak

Epidemiology and Infection

Volumn 140, Issue 6, 2012, Pages 1028-1035

  Lee, S H ^a   Yim, J J ^b   Kim, H J ^c   Shim, T S ^d   Seo, H S ^e   Cho, Y S ^e   Lee, H K ^a   Lee, Y M ^a   Lee, E J ^f   Lew, W J ^c,g  

^a Inje University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Korean Institute of Tuberculosis   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Seobuk Hospital   (South Korea)

^f Public Healthcare Center   (South Korea)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antibiotic prophylaxis; drug toxicity; multidrug resistant tuberculosis; rifampicin; tuberculosis

Indexed keywords

BCG VACCINE; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIUM CULTURE; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ECCHYMOSIS; EPIDEMIC; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYALGIA; PETECHIA; PRESCRIPTION; SCREENING; SIDE EFFECT; SKIN TOXICITY; SMEAR; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; DISEASE OUTBREAKS; FEMALE; GROUP HOMES; HUMANS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RIFAMPIN; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84861094516     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268811001476     Document Type: Article

References (33)

1. World Health Organization. The global plan to stop TB 2011-2015. Geneva: WHO, 2010. Report No. WHO/HTM/STB/2010.2 (http://www.who.int/tb/publications/ 2010/eng.pdf). Accessed 3 January 2011.
2. Corbett EL, et al. The growing burden of tuberculosis : global trends and interactions with the HIV epidemic. Archives of Internal Medicine 2003; 163: 1009-1021.
3. Dye C, et al. Consensus statement. Global burden of tuberculosis : estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Journal of the American Medical Association 1999; 282: 677-686.
4. Broekmans JF, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. European Respiratory Journal 2002; 19: 765-775.
5. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. New England Journal of Medicine 2002; 347: 1860-1866.
6. American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Journal of Respiratory and Critical Care Medicine 2000; 161: S221-247.
7. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection : Areas of uncertainty and recommendations for research. Annals of Internal Medicine 2007; 146: 340-354.
8. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection : An update. Annals of Internal Medicine 2008; 149: 177-184.
9. Bakir M, et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Annals of Internal Medicine 2008; 149: 777-787.
10. Yoshiyama T, et al. Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. International Journal of Tuberculosis and Lung Disease 2010; 14: 819-827.
11. Kik SV, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. European Respiratory Journal 2010; 35: 1346-1353.
12. Diel R, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine 2008; 177: 1164-1170.
13. Mori T, Harada N. Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations. Kekkaku 2005; 80: 675-686.
14. Menzies D, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection : A randomized trial. Annals of Internal Medicine 2008; 149: 689-697.
15. Menzies D, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. American Journal of Respiratory and Critical Care Medicine 2004; 170: 445-449.
16. Blumberg HM, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine 2003; 167: 603-662.
17. Holdiness MR. A review of blood dyscrasias induced by the antituberculosis drugs. Tubercle and lung disease 1987; 68: 301-309.
18. Livengood JR, et al. Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. Journal of the American Medical Association 1985; 253: 2847-2849.
19. Balcells ME, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerging Infectious Diseases 2006; 12: 744-751.
20. Lee SH, et al. Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. Respiratory Medicine 2010; 104: 448-453.
21. Korea Center for Disease Control. National guidelines for managing tuberculosis. KCDC guideline 2007, pp. 133-141.
22. Grosset J, Leventis S. Adverse effects of rifampin. Reviews of Infectious Diseases 1983; 5: S440-S450.
23. Blajchman MA, et al. Rifampicin-induced immune thrombocytopenia. British Medical Journal 1970; 3: 24-26.
24. Martnez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine 1999; 78: 361-369.
25. Girling DJ. Adverse reactions to rifampicin in antituberculosis regimens. Journal of Antimicrobial Chemotherapy 1977; 3: 115-132.
26. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. American Journal of Respiratory and Critical Care Medicine 2003; 168: 443-447.
27. Lobue P, Menzies D. Treatment of latent tuberculosis infection : An update. Respirology 2010; 15: 603-622.
28. Anon. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. American Review of Respiratory Disease 1992; 145: 36-41.
29. Villarino ME, et al. Rifampin preventive therapy for tuberculosis infection : experience with 157 adolescents. American Journal of Respiratory and Critical Care Medicine 1997; 155: 1735-1738.
30. Polesky A, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. American Journal of Respiratory and Critical Care Medicine 1996; 154: 1473-1477.
31. Nolan CM, et al. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. American Review of Respiratory Disease 1986; 133: 431-436.
32. Bai GH, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. International Journal of Tuberculosis and Lung Disease 2007; 11: 571-576.
33. Lee S, et al. The role of chest CT scanning in TB outbreak investigation. Chest 2010; 137: 1057-1064.